摘要
目的探讨淋系抗原在急性髓系白血病细胞上的表达及意义。方法采用间接免疫荧光法检测182例急性髓系白血病细胞的免疫表型。根据FAB亚型和免疫标志将病例分为2组:伴淋系相关抗原的急性髓细胞性白血病(Ly+AML),不伴淋系相关抗原的急性髓细胞性白血病(Ly-AML)。结果182例AML中有64例表达淋系抗原(33%),CD+7在AML中表达率为54.7%,M0中阳性率最高100%,M1次之78%。Ly+AML组的白细胞、血小板数高于Ly-AML,有显著性差异。Ly+AML组与Ly-AML组的诱导缓解率及临床特征无显著性差异。Ly+AML组和Ly-AML组比较,平均缓解期较短。结论CD+7AML与AML蛳M0、M1有着密切的关系,可以看作是一个独特的临床亚型。Ly+AML较之Ly-AML具有不同的临床特征和短CR期。Ly+AML的出现可以作为危险因子中的一个因子来选择更合适的化疗也许是必要的。
Objective To explore the clinical significance of lymphoid antigens expression in acute myelogenous leukemia. Methods Immunophenotypes were examined using indireat immunofluoresence method in 182 patients with AML. All patients are classified into to groups cording to FAB subtypes and immunophenotyes: acute myeloid leukemia displaying lymphoid surface markers (Ly+AML),acute myeloid leukemia displaying no lymphoid surface markers(Ly-AML). Results The expression of lymphoid antigens in 182 cases of AML observed at our institution, 64 cases (33 %) carried lymphoid antigens. CD+7 35 cases (54.7 %). Incidence of CD+7 expression in each FAB subtype was also different. CD+7 expression were signficanty more frequent in AML- M0?M1 (100 %, 78 %, respectively). The typical characteristic in CD AML was CD34 high. The WBC and BPC count of Ly+AML patients are higher than Ly-AML patients have significant difference. The complete remission rate and clinical characteristics between Ly+AML patients and Ly-AML patients have no significant difference. The median remission duration of Ly+AML patients are relatively shorter than Ly-AML patients. Conclusions Thers was relationship between the CD+34 expression and FAB subtyes (M0, M1), it may present a particular subset of AML. Ly+AML are differ from Ly-AML on clinical characteristics and shorter CR durations. The appearance of Ly+AML indicates the patient had one of the high risk factors, so it is necessary to select individalzed chemotherapy protocol for them.
出处
《白血病.淋巴瘤》
CAS
2005年第1期14-16,共3页
Journal of Leukemia & Lymphoma
基金
新疆维吾尔自治区科技厅自然科学基金资助项目(200121102)
关键词
急性髓系白血病
淋系分化抗原
免疫表型
Acute myeloid leukemia
Lymphoid differentiation antigen
Immunophenotype